In this project, we aim to develop a robust and high efficient system for removal of undifferentiated cells from hPSC-derived cardiomyocytes to eliminate the risk of tumorigenesis in a patient. We therefore propose to use the method we previously developed for capturing rare cells, such as EPCs and CTCs in blood. Specifically, we planned to apply a microfluidic device with fishing net-like micro-pillar arrays in efficient capture of undifferentiated hPSCs in a solution of hPSCs-derived cardiomyocytes. For the second phase, we will integrate nano-engineered substrates, such as nanofibers into our capturing devices to increase the efficiency to remove undifferentiated hPSCs.
「研究計画及び実績」: Last year, we have finished the design and the fabrication of the microfluidic chip, and set up a mini, easy to handle platform for the purification of hPSCs-derived cardiomyocytes. We then proved that the viability of cardiomyocytes after circulating in the microfluidic-chip. The capture rate of certain type of cells can be up to 80%, paper about this work is now under preparation.
Our work in last year have validated the feasibility of removal small amount of undifferentiated cells from hPSC-derived cardiomyocytes. The viability and the capture rate have been both verified. The parameters in the microfluidics, such like flow rate, circulation mode, and the cell types have been characterized. We are close to finish the first aim in our proposal.